Tandem Diabetes (TNDM) Tops Q4 EPS by 22c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Tandem Diabetes Care (TNDM) PT Lowered to $35 at Citi
February 27, 2025 5:42 AM ESTCiti analyst Joanna Wuensch lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $35.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "Tandem delivered 4Q24 revenue that was modestly higher than expectations, delivering $252.4M (up 20.6%) ahead of consensuss $249.7M,... More
